Replies to post #28841 on Biotech Values

[spartex]

Dew, re: REGN

In terms of time, how long would it take for REGN to complete their necessary Phase II and III trials and go through an FDA review on their VEGF Trap in Age-Related Macular Degeneration?

Any thoughts on the other drug trials that REGN has underway, versus the stocks current valuation?

I bought into the stock last year in the $5's, sold 1/2 at around $17, and am starting to re-enter a larger position again with the recent sell off. I need to pay attention to DNA's Lucentis Phase IIIb PIER data results symposium on June 2 to see if it may impact REGN's share price further.

Thanks